Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 6Carcinoma, Hepatocellular 2Uveal Melanoma 1Prostatic Neoplasms 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Renal Cell 1Amyloidosis 1

Interventions

pembrolizumab 36Nivolumab 32Bevacizumab 13Sunitinib 10Ipilimumab 10aldesleukin 7Interleukin-2 7Axitinib 7lenvatinib 6cabozantinib 6Paclitaxel 6Everolimus 6Docetaxel 6Cyclosporine 6Cyclophosphamide 6fludarabine phosphate 5Sorafenib 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5fludarabine 4cemiplimab 4belzutifan 4Whole-Body Irradiation 4Radiosurgery 4Interferon-alpha 4Cetuximab 4durvalumab 3bempegaldesleukin 3avelumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Renal Cell × Thalidomide × Clear all
NCT00277017 2011-09-27

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

New Mexico Cancer Research Alliance

Phase 1/2 Completed
15 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡